Table S1.
EPM behavior, tph2 mRNA expression, and slc6a4 mRNA expression data from Exps. 1, 2, and 4
| Vehicle | M. vaccae | |||
| Data in experiments | SHC | CSC | SHC | CSC |
| Elevated plus-maze data | ||||
| Exp. 1 | ||||
| Entries in open arms (n) | 11.57 ± 1.78 | 11.33 ± 0.96 | 9.33 ± 0.93 | 12.31 ± 1.08 |
| Entries in closed arms (n) | 18.67 ± 1.69 | 19.92 ± 1.40 | 20.44 ± 1.02 | 21.50 ± 1.33 |
| Percent entries in open arms (%) | 35.32 ± 2.60 | 36.37 ± 1.82 | 30.89 ± 1.67 | 35.65 ± 1.75 |
| †Time spent in open arms (s) | 36.68 ± 7.32 | 42.21 ± 3.39 | 26.75 ± 3.17 | 50.87 ± 5.46++ |
| ‡Time spent in closed arms (s) | 226.43 ± 5.90 | 214.36 ± 3.12 | 228.91 ± 4.69 | 203.34 ± 6.95++ |
| Percent time spent in open arms (%) | 13.02 ± 2.48 | 16.42 ± 1.28 | 10.41 ± 1.18 | 20.16 ± 2.18++ |
| Latency to first entry of open arms (s) | 19.23 ± 1.48 | 12.87 ± 3.90 | 33.25 ± 11.55 | 16.41 ± 3.14 |
| §Full entries of open arms (n) | 0.50 ± 0.34 | 1.42 ± 0.36 | 0.38 ± 0.26 | 1.56 ± 0.50 |
| Exp. 2 | ||||
| Entries in open arms (n) | 4.50 ± 1.24 | 8.00 ± 0.89* | ||
| Entries in closed arms (n) | 10.13 ± 1.77 | 14.00 ± 0.62 | ||
| Percent entries in open arms (%) | 24.28 ± 6.12 | 35.34 ± 2.80 | ||
| Time spent in open arms (s) | 15.88 ± 3.92 | 46.04 ± 6.80** | ||
| Time spent in closed arms (s) | 256.09 ± 10.25 | 213.09 ± 7.54** | ||
| Percent time spent in open arms (%) | 6.06 ± 1.53 | 17.76 ± 2.58** | ||
| Latency to first entry of open arms (s) | 141.33 ± 38.58 | 30.72 ± 11.96* | ||
| Full entries of open arms (n) | 0.00 ± 0.00 | 1.63 ± 0.56* | ||
| M. vaccae | ||||
| +Control antibody | +Anti-CD25 antibody | |||
| SHC | CSC | SHC | CSC | |
| Exp. 4 | ||||
| ¶Entries in open arms (n) | 4.29 ± 0.84 | 7.00 ± 1.15 | 2.80 ± 0.97 | 2.14 ± 0.40** |
| Entries in closed arms (n) | 10.57 ± 2.23 | 11.50 ± 1.89 | 9.80 ± 0.86 | 8.00 ± 2.25 |
| ‖Percent entries in open arms (%) | 28.86 ± 1.49 | 38.42 ± 4.05 | 20.38 ± 5.54 | 20.96 ± 4.69** |
| ††Time spent in open arms (s) | 21.47 ± 4.86 | 55.24 ± 12.51 | 13.85 ± 4.45 | 10.51 ± 2.73*** |
| ‡‡Time spent in closed arms (s) | 236.69 ± 12.92 | 195.99 ± 16.06+ | 251.15 ± 13.30 | 249.59 ± 10.23 |
| Percent time spent in open arms (%) | 8.60 ± 1.99 | 22.24 ± 4.94++ | 5.47 ± 1.93 | 3.88 ± 0.99*** |
| Latency to first entry of open arm (s) | 123.24 ± 40.74 | 33.83 ± 12.01 | 129.77 ± 38.02 | 133.61 ± 35.74 |
| §§Full entries of open arms (n) | 0.86 ± 0.40 | 2.83 ± 0.65++ | 0.60 ± 0.24 | 0.29 ± 0.18*** |
| Vehicle | M. vaccae | |||
| SHC | CSC | SHC | CSC | |
| tph2 mRNA expression in subdivisions of the DR and MnR | ||||
| Exp. 1 | ||||
| rDRD | 1.87 ± 0.11 | 1.84 ± 0.19 | 2.37 ± 0.06** | 2.42 ± 0.18** |
| cDRD | 1.94 ± 0.06 | 1.89 ± 0.09 | 1.94 ± 0.08 | 1.80 ± 0.15 |
| rDRV | 2.59 ± 0.13 | 2.55 ± 0.15 | 2.86 ± 0.23 | 2.60 ± 0.15 |
| cDRV | 2.54 ± 0.14 | 2.34 ± 0.10 | 2.50 ± 0.10 | 2.16 ± 0.20 |
| DRVL/VLPAG | 1.38 ± 0.04 | 1.36 ± 0.04 | 1.40 ± 0.05 | 1.24 ± 0.07 |
| DRC | 1.43 ± 0.05 | 1.62 ± 0.12 | 1.56 ± 0.06 | 1.38 ± 0.06 |
| DRI | 1.36 ± 0.05 | 1.35 ± 0.03 | 1.47 ± 0.08 | 1.33 ± 0.05 |
| Entire DR, average | 1.72 ± 0.04 | 1.74 ± 0.03 | 1.84 ± 0.06 | 1.66 ± 0.04 |
| rMnR | 0.92 ± 0.03 | 1.02 ± 0.05 | 1.09 ± 0.10 | 1.13 ± 0.07 |
| cMnR | 0.71 ± 0.03 | 0.83 ± 0.02 | 0.81 ± 0.06 | 0.86 ± 0.06 |
| M. vaccae | ||||
| +Control antibody | +Anti-CD25 antibody | |||
| SHC | CSC | SHC | CSC | |
| Exp. 4 | ||||
| rDRD | 3.24 ± 0.17 | 3.32 ± 0.16 | 3.36 ± 0.06 | 3.21 ± 0.27 |
| cDRD | 3.10 ± 0.28 | 2.80 ± 0.24 | 2.68 ± 0.18 | 3.07 ± 0.25 |
| rDRV | 3.60 ± 0.09 | 3.35 ± 0.27 | 3.43 ± 0.23 | 3.59 ± 0.33 |
| cDRV | 3.08 ± 0.22 | 3.10 ± 0.17 | 3.05 ± 0.18 | 2.83 ± 0.27 |
| DRVL/VLPAG | 2.07 ± 0.10 | 2.13 ± 0.11 | 2.16 ± 0.13 | 2.16 ± 0.16 |
| DRC | 2.87 ± 0.17 | 2.39 ± 0.04 | 2.62 ± 0.05 | 2.74 ± 0.12 |
| DRI | 1.91 ± 0.08 | 1.92 ± 0.09 | 2.23 ± 0.13* | 2.13 ± 0.17* |
| Entire DR, average | 2.50 ± 0.05 | 2.37 ± 0.04 | 2.46 ± 0.06 | 2.49 ± 0.09 |
| rMnR | 1.40 ± 0.05 | 1.85 ± 0.01++ | 1.70 ± 0.05** | 1.68 ± 0.04 |
| cMnR | 1.23 ± 0.07 | 1.29 ± 0.06 | 1.21 ± 0.07 | 1.30 ± 0.08 |
| Vehicle | M. vaccae | |||
| SHC | CSC | SHC | CSC | |
| slc6a4 mRNA expression in subdivisions of the DR and MnR | ||||
| Exp. 1 | ||||
| rDRD | 3.78 ± 0.22 | 2.9 ± 0.21++ | 3.55 ± 0.29 | 3.13 ± 0.37 |
| cDRD | 3.46 ± 0.24 | 3.69 ± 0.20 | 3.72 ± 0.52 | 3.23 ± 0.41 |
| rDRV | 3.87 ± 0.44 | 3.28 ± 0.17 | 4.14 ± 0.37 | 3.11 ± 0.25+ |
| cDRV | 5.34 ± 0.98 | 4.68 ± 0.77 | 6.44 ± 1.23 | 4.40 ± 0.58 |
| DRVL/VLPAG | 2.43 ± 0.22 | 2.17 ± 0.08 | 2.37 ± 0.34 | 2.12 ± 0.04 |
| DRC | 2.17 ± 0.09 | 1.85 ± 0.15+ | 2.29 ± 0.12 | 2.23 ± 0.11* |
| DRI | 2.51 ± 0.23 | 2.33 ± 0.13 | 2.17 ± 0.19 | 2.17 ± 0.07 |
| Entire DR, average | 3.11 ± 0.23 | 2.75 ± 0.12 | 3.34 ± 0.32 | 2.65 ± 0.13 |
| rMnR | 1.78 ± 0.21 | 1.5 ± 0.25 | 1.97 ± 0.24 | 1.52 ± 0.90 |
| cMnR | 1.72 ± 0.12 | 1.5 ± 0.05 | 2.15 ± 0.35 | 1.52 ± 0.10+ |
| M. vaccae | ||||
| +Control antibody | +Anti-CD25 antibody | |||
| SHC | CSC | SHC | CSC | |
| Exp. 4 | ||||
| rDRD | 1.76 ± 0.15 | 1.82 ± 0.17 | 1.68 ± 0.20 | 1.82 ± 0.12 |
| cDRD | 1.52 ± 0.17 | 1.55 ± 0.13 | 1.62 ± 0.15 | 1.51 ± 0.09 |
| rDRV | 2.42 ± 0.25 | 1.87 ± 0.14 | 1.75 ± 0.23* | 1.95 ± 0.12 |
| cDRV | 1.56 ± 0.13 | 1.61 ± 0.14 | 1.48 ± 0.11 | 1.45 ± 0.16 |
| DRVL/VLPAG | 1.09 ± 0.05 | 1.09 ± 0.09 | 1.03 ± 0.09 | 1.04 ± 0.08 |
| DRC | 1.19 ± 0.11 | 1.12 ± 0.08 | 0.96 ± 0.08 | 1.02 ± 0.06 |
| DRI | 1.13 ± 0.09 | 1.08 ± 0.13 | 0.98 ± 0.08 | 0.88 ± 0.05 |
| Entire DR, average | 1.35 ± 0.08 | 1.29 ± 0.09 | 1.19 ± 0.10 | 1.22 ± 0.06 |
| rMnR | 1.09 ± 0.07 | 1.10 ± 0.08 | 0.97 ± 0.08 | 1.13 ± 0.13 |
| cMnR | 0.80 ± 0.09 | 0.88 ± 0.09 | 0.74 ± 0.05 | 0.82 ± 0.09 |
+P < 0.05, ++P < 0.01, CSC versus SHC, EPM, Exp. 1, Exp. 4, Fisher's least significant difference tests; tph2 mRNA expression, Exp. 4, Fisher's least significant difference tests; slc6a4 mRNA expression, Exp. 1, Fisher's least significant difference tests; *P < 0.05, **P < 0.01, ***P < 0.001, vehicle versus M. vaccae, EPM, Exp. 2, Student's t tests; control antibody versus anti-CD25 antibody, EPM, Exp. 4, Fisher's least significant difference tests; vehicle versus M. vaccae, tph2 mRNA expression, Exp. 1, Fisher's least significant difference tests; control antibody versus anti-CD25 antibody, tph2 mRNA expression, Exp. 4, Fisher's least significant difference tests; vehicle versus M. vaccae, slc6a4 mRNA expression, Exp. 1, Fisher's least significant difference tests.
Two-factor ANOVA, CSC, F(1, 40) = 9.2, P < 0.01.
Two-factor ANOVA, CSC, F(1, 40) = 8.9, P < 0.01.
Two-factor ANOVA, CSC, F(1, 38) = 4.6, P < 0.05.
Two-factor ANOVA, anti-CD25 antibody, F(1, 21) = 13.6, P < 0.01.
Two-factor ANOVA, anti-CD25 antibody, F(1, 21) = 10.2, P < 0.01.
Two-factor ANOVA, anti-CD25 antibody × CSC, F(1, 21) = 6.9, P < 0.05.
Two-factor ANOVA, anti-CD25 antibody, F(1, 21) = 6.6, P < 0.05.
Two-factor ANOVA, anti-CD25 antibody × CSC, F(1, 21) = 7.6, P < 0.05.